v3.25.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue:    
Total revenue $ 9,182,000 $ 9,154,000
Cost of revenue:    
Total cost of revenue 3,703,000 3,892,000
Gross profit 5,479,000 5,262,000
Operating expenses:    
Research and development 3,266,000 4,035,000
Sales and marketing 8,146,000 7,812,000
General and administrative 10,345,000 12,267,000
Total operating expenses 21,757,000 24,114,000
Loss from operations (16,278,000) (18,852,000)
Other income, net:    
Change in fair value of warrant liabilities 1,346,000 629,000
Interest income (expense), net (33,000) 48,000
Forgiveness of DECD loan 1,000,000
Other income, net 1,871,000 485,000
Total other income, net 3,184,000 2,162,000
Net loss $ (13,094,000) $ (16,690,000)
Net loss per share - diluted $ (0.93) $ (1.81)
Net loss per share - basic $ (0.93) $ (1.81)
Basic weighted average common shares used to compute net loss per common share 14,134,626 9,233,306
Diluted weighted average common shares used to compute net loss per common share 14,134,626 9,233,306
Product [Member]    
Revenue:    
Total revenue $ 9,182,000 $ 9,153,000
Cost of revenue:    
Total cost of revenue 3,703,000 3,892,000
Genetics [Member]    
Revenue:    
Total revenue 1,000
Cost of revenue:    
Total cost of revenue